According to filings with the U.S. Securities and Exchange Commission, Cleerly is raising up to $106,307,369.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Cleerly
Cleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for the diagnosis of heart disease. Through its AI-empowered solutions, Cleerly supports comprehensive phenotyping of coronary artery disease, through its evaluation of advanced non-invasive CT imaging. Cleerlys approach is grounded in nearly 20 years of science from landmark multi-center clinical trials. Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway.

To learn more about Cleerly, visit http://www.cleerlyhealth.com/
Cleerly Linkedin Page: https://www.linkedin.com/company/cleerlyhealth/

Contact:
James Min, President and Chief Executive Officer
720-213-8256
https://www.linkedin.com/in/jameskminmd/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.